Turning Pap Test into Sequencing-Based Gynecologic Cancer Assay will Take Further Validation | GenomeWeb

Following last month's publication of a study that suggested the Papanicolaou test, or Pap smear, could potentially be repurposed as a sequencing-based screening test for endometrial and ovarian cancer, the authors are now working on validating the results, hoping to develop a routine clinical test for the early detection of cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.